Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1204-1212

  Ko, Eunkyung ^a   Lee, Bo Bin ^a   Kim, Yujin ^a   Lee, Eun Ju ^a   Cho, Eun Yoon ^b   Han, Jungho ^b   Shim, Young Mog ^b   Park, Joobae ^a   Kim, Duk Hwan ^a  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; PROTEIN BCL 2; PROTEIN P53; PROTEIN P63; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84874819162     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2848     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58: 71-96.
2. Gilbert S, Reid KR, Lam MY, Petsikas D. Who should follow up lung cancer patients after operation? Ann Thorac Surg 2000;69: 1696-700.
3. KimJS, KimJW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66: 4049-54.
4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349: 2042-54.
5. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El- Naggar AK, et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 2000;97: 4174-9.
6. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119: 847-60.
7. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010;107: 246-51.
8. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161: 1199-206.
9. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002;9: 216-9.
10. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003;9: 5501-7.
11. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 2006;66: 7589-97.
12. Gu X, Coates PJ, Boldrup L, Nylander K. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett 2008;263: 26-34.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Troth A. American Joint Committee on Cancer. In: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 253-70.
14. Ko E, Park SE, Cho EY, Kim Y, Hwang JA, Lee YS, et al. CystatinMloss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Breast Cancer Res 2010;12:R100.
15. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNAmethylation markers and early recurrence in stage I lung cancer.N Engl J Med 2008;358: 1118-28.
16. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010;126: 1630-9.
17. de Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, et al. Intergroupe Francophone de Cancérologie Thoracique. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res 2012;18: 2976-86.
18. Wang J, Wang B, Chen X, Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 2011;32: 411-6.
19. Kim JS, Lee H, Kim H, Shim YM, Han J, Park J, et al. Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. J Clin Oncol 2004;22: 3443-50
20. Gao P, Yang X, Xue YW, Zhang XF, Wang Y, Liu WJ, et al. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. Cancer 2009;115: 3222-32.
21. Grimminger PP, Maus MK, Schneider PM, Metzger R, Hölscher AH, Sugita H, et al. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC. Lung Cancer 2012;78: 87-91.
22. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59: 790-800.
23. Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, et al. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 2004;112: 1003-9.
24. Widschwendter A,Müller HM, Fiegl H, Ivarsson L, Wiedemair A,Müller- Holzner E, et al. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 2004;10: 565-71.
25. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, et al. HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008;123: 725-9
26. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72: 2197-205.
27. Lee EJ, Lee BB, Han J, Cho EY, Shim YM, Park J, et al. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer 2008;123: 2073-9.
28. Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, et al. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung. Lung Cancer 2005;50: 67-73.
29. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63: 7113-21.
30. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198: 100-9.
31. Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein LA, et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 2004;101: 1632-8.
32. Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, et al. BCL-2 expression is prognostic for improved survival in nonsmall cell lung cancer. J Thorac Oncol 2009;4: 486-91.
33. Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204: 101-9.
34. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000;275: 35669-72.
35. Hamilton G, Yee KS, Scrace S, O'Neill E. ATM regulates a RASSF1Adependent DNA damage response. Curr Biol 2009;19: 2020-5.
36. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002;22: 4309-18.
37. Endoh H, Yatabe Y, Shimizu S, Tajima K, Kuwano H, Takahashi T, et al. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 2003;106: 45-51
38. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398: 708-13.
39. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398: 714-8.
40. Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 2006;133: 1553-63.
41. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2: 305-16.
42. Bourdon JC. p53 Family isoforms. Curr Pharm Biotechnol 2007;8: 332-6.
43. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumorderived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001;21: 1874-87.
44. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002;277: 18817-26.
45. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7: 363-73.
46. Li Y, PrivesC. Are interactions with p63 and p73 involved inmutant p53 gain of oncogenic function? Oncogene 2007;26: 2220-5.
47. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009;137: 87-98.
48. Strauss GM,Herndon JE II, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26: 5043-51.